作者
Kathryn M Kingsmore, Amrie C Grammer, Peter E Lipsky
发表日期
2020/1
来源
Nature Reviews Rheumatology
卷号
16
期号
1
页码范围
32-52
出版商
Nature Publishing Group UK
简介
The past century has been characterized by intensive efforts, within both academia and the pharmaceutical industry, to introduce new treatments to individuals with rheumatic autoimmune inflammatory diseases (RAIDs), often by ‘borrowing’ treatments already employed in one RAID or previously used in an entirely different disease, a concept known as drug repurposing. However, despite sharing some clinical manifestations and immune dysregulation, disease pathogenesis and phenotype vary greatly among RAIDs, and limited understanding of their aetiology has made repurposing drugs for RAIDs challenging. Nevertheless, the past century has been characterized by different ‘waves’ of repurposing. Early drug repurposing occurred in academia and was based on serendipitous observations or perceived disease similarity, often driven by the availability and popularity of drug classes. Since the 1990s, most …
学术搜索中的文章
KM Kingsmore, AC Grammer, PE Lipsky - Nature Reviews Rheumatology, 2020